Exousia Pro Reports Positive Outcome in Legal Proceeding
Exousia Pro (OTCPINK:MAJI), a clinical-stage biotechnology company, reported positive developments in its legal proceedings against former CEO Donald Steinberg and related shareholders. The company secured a standstill order on approximately 10.5% of outstanding shares held by the former CEO.
Additionally, Exousia Pro executed two rescission agreements blocking legend removal on 3,250,000 shares (approximately 8% of outstanding shares). While the Temporary Restraining Order hearing was not conducted, the company achieved significant shareholder protections through these legal measures.
The company plans to refocus on its core business of developing exosome-based cancer therapies and will provide updates on ongoing studies, therapies, and patents.
Exousia Pro (OTCPINK:MAJI), un’azienda biotecnologica in fase clinica, ha annunciato progressi positivi nelle procedure legali contro l’ex CEO Donald Steinberg e gli azionisti correlati. Ha ottenuto un’ordinanza di standstill su circa il 10,5% delle azioni in circolazione detenute dall’ex CEO.
Inoltre, Exousia Pro ha stipulato due accordi di rescissione che impediscono la rimozione della legenda su 3.250.000 azioni (circa l’8% delle azioni in circolazione). Sebbene l’udienza per l’Ordinanza di Motivi Temporanei non sia stata svolta, l’azienda ha conseguito significative protezioni per gli azionisti tramite queste misure legali.
L’azienda intende tornare a concentrarsi sul proprio core business, lo sviluppo di terapie oncologiche basate su esosomi, e fornirà aggiornamenti sugli studi in corso, sulle terapie e sui brevetti.
Exousia Pro (OTCPINK:MAJI), una empresa biofarmacéutica en fase clínica, informó avances positivos en sus procesos legales contra el ex CEO Donald Steinberg y accionistas relacionados. La compañía obtuvo una orden de inmovilización sobre aproximadamente el 10,5% de las acciones en circulación poseídas por el ex CEO.
Además, Exousia Pro ejecutó dos acuerdos de rescisión que bloquean la retirada de la leyenda sobre 3.250.000 acciones (aproximadamente el 8% de las acciones en circulación). Aunque la audiencia de la Orden de Restricción Temporal no se llevó a cabo, la empresa logró protecciones significativas para los accionistas mediante estas medidas legales.
La compañía planea volver a centrarse en su negocio principal de desarrollar terapias contra el cáncer basadas en exosomas y proporcionará actualizaciones sobre los estudios en curso, las terapias y las patentes.
Exousia Pro (OTCPINK:MAJI)는 임상 단계의 생명공학 회사로, 전 CEO인 Donald Steinberg 및 관련 주주들에 대한 법적 절차에서 긍정적 진전을 보고했습니다. 회사는 전 CEO가 보유한 발행 주식의 약 10.5%에 해당하는 주식에 대해 동결 명령을 확보했습니다.
또한 Exousia Pro는 3,250,000주(약 8%의 발행 주식)에 대해 주석 제거를 차단하는 두 건의 해제 계약을 체결했습니다. 임시 금지 명령 청문회가 열리지는 않았지만, 이러한 법적 조치를 통해 주주 보호를 크게 달성했습니다.
회사는 엑소좀 기반의 암 치료제 개발이라는 핵심 사업에 다시 집중할 계획이며, 진행 중인 연구, 치료 및 특허에 대해 업데이트를 제공할 것입니다.
Exousia Pro (OTCPINK:MAJI), une entreprise biotechnologique en phase clinique, a annoncé des développements positifs dans ses procédures judiciaires contre l’ancien PDG Donald Steinberg et les actionnaires concernés. La société a obtenu une ordonnance de suspension sur environ 10,5% des actions en circulation détenues par l’ancien PDG.
De plus, Exousia Pro a conclu deux accords de rescission bloquant le retrait de la légende sur 3 250 000 actions (environ 8% des actions en circulation). Bien que l’audience de l’Ordonnance de Restriction Temporaire n’ait pas eu lieu, l’entreprise a obtenu des protections importantes pour les actionnaires grâce à ces mesures juridiques.
La société prévoit de se recentrer sur son cœur de métier, le développement de thérapies anticancéreuses basées sur les exosomes, et fournira des mises à jour sur les études en cours, les thérapies et les brevets.
Exousia Pro (OTCPINK:MAJI), ein biotechnologisches Unternehmen in klinischer Phase, meldete positive Entwicklungen in seinen Rechtsstreitigkeiten gegen den ehemaligen CEO Donald Steinberg und beteiligte Aktionäre. Das Unternehmen erwirkte eine Standstill-Vereinbarung über etwa 10,5% der ausstehenden Aktien, die sich im Besitz des ehemaligen CEO befinden.
Zusätzlich hat Exousia Pro zwei Rücktrittsvereinbarungen geschlossen, die die Entfernung der Legende bei 3.250.000 Aktien (etwa 8% der ausstehenden Aktien) blockieren. Obwohl die Anhörung der Temporary-Restraining-Order-Verfügung nicht stattfand, erreichte das Unternehmen durch diese Rechtsmaßnahmen wichtigen Aktionärenschutz.
Das Unternehmen plant, sich wieder auf sein Kerngeschäft der Entwicklung exosom-basierter Krebsbehandlungen zu konzentrieren und wird Updates zu laufenden Studien, Therapien und Patenten bereitstellen.
Exousia Pro (OTCPINK:MAJI)، شركة تكنولوجيا حيوية في المرحلة السريرية، أعلنت عن تطورات إيجابية في إجراءاتها القانونية ضد الرئيس التنفيذي السابق دونالد ستاينبرغ والمديرين المساهمين ذوي الصلة. حصلت الشركة على أمر وقف مؤقت لحوالي 10.5% من الأسهم القائمة التي يملكها المدير التنفيذي السابق.
بالإضافة إلى ذلك، وقّعت Exousia Pro اتفاقيتين لإلغاء القيود تمنع إزالة الشارة على 3,250,000 سهم (حوالي 8% من الأسهم القائمة). على الرغم من عدم عقد جلسة أمر التقييد المؤقت، إلا أن الشركة حققت حماية كبيرة للمساهمين من خلال هذه الإجراءات القانونية.
تخطط الشركة للتركيز من جديد على أعمالها الأساسية في تطوير علاجات سرطان قائمة على الإكسوزومات وستقدم تحديثات حول الدراسات الجارية والعلاجات وحقوق الملكية.
Exousia Pro (OTCPINK:MAJI)，处于临床阶段的生物技术公司，宣布在对前任CEO Donald Steinberg及相关股东的法律程序中取得积极进展。公司就前CEO所持的约10.5%的在外流通股获得了停滞令。
此外，Exousia Pro签署了两项撤销协议，阻止对3,250,000股（约占在外流通股的8%）实施图例移除。尽管暂时禁令听证会未举行，但通过这些法律措施，公司为股东提供了重要保护。
公司计划将重点重新放回核心业务，即开发基于外泌体的癌症治疗，并将就正在进行的研究、治疗和专利提供更新。
- Successful execution of standstill order on 10.5% of shares held by former CEO
- Implementation of rescission agreements blocking legend removal on 3,250,000 shares (8% of outstanding shares)
- Legal proceedings advancing favorably to protect shareholder interests
- Temporary Restraining Order (TRO) motion not heard due to court time constraints
Focused on Protecting Shareholder Value and Advancing Core Business
ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on exosome-based therapies, today issued a positive update regarding its legal proceedings against Donald Steinberg, the former sole officer and director, and other related shareholders.
Following a hearing held yesterday, the company is pleased to report that significant protections for shareholders have been put in place. While the motion for a Temporary Restraining Order (TRO) was not heard due to a lack of available court time, a mutually agreed-upon standstill order was executed on all shares held by the former CEO, representing approximately
In a further proactive measure, Exousia Pro executed two rescission agreements. These agreements will be used to block the removal of legends on an additional 3,250,000 shares, representing approximately
"We are very pleased with the outcome of the hearing, as key protections were secured for our shareholders," stated Matt Dwyer, President of Exousia Pro, Inc. "Our legal strategy is focused on a surgical approach to achieve our objectives and protect our shareholders' interests. This successful step allows us to refocus our full attention on our primary mission: developing innovative exosome therapies for the cancer market."
Exousia Pro is now fully committed to driving forward its business objectives with renewed energy and focus. The company will be releasing new and exciting updates on its ongoing studies, therapies, nutraceutical products, patents, and expansion initiatives.
About Us
Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Exousia Pro, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Exousia Pro, Inc.
View the original press release on ACCESS Newswire
FAQ
What legal protections did Exousia Pro (MAJI) secure for shareholders in September 2025?
How many shares are affected by Exousia Pro's (MAJI) recent legal agreements?
What was the outcome of Exousia Pro's (MAJI) Temporary Restraining Order hearing?
What is Exousia Pro's (MAJI) business focus following the legal proceedings?
